SEARCH

SEARCH BY CITATION

References

  • 1
    Couch FJ,Farid LM,DeShano ML,Tavtigian SV,Calzone K,Campeau L,Peng Y,Bogden B,Chen Q,Neuhausen S,Shattuck-Eidens D,Godwin AK, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996; 13: 1235.
  • 2
    Phelan CM,Lancaster JM,Tonin P,Gumbs C,Cochran C,Carter R,Ghadirian P,Perret C,Moslehi R,Dion F,Faucher MC,Dole K, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996; 13: 1202.
  • 3
    FitzGerald MG,MacDonald DJ,Krainer M,Hoover I,O'Neil E,Unsal H,Silva-Arrieto S,Finkelstein DM,Beer-Romero P,Englert C,Sgroi DC,Smith BL, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334: 1439.
  • 4
    Krainer M,Silva-Arrieta S,FitzGerald MG,Shimada A,Ishioka C,Kanamaru R,MacDonald DJ,Unsal H,Finkelstein DM,Bowcock A,Isselbacher KJ,Haber DA. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 1997; 336: 141621.
  • 5
    Langston AA,Malone KE,Thompson JD,Daling JR,Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996; 334: 13742.
  • 6
    Lichtenstein P,Holm NV,Verkasalo PK,Iliadou A,Kaprio J,Koskenvuo M,Pukkala E,Skytthe A,Hemminki K. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 7885.
  • 7
    Antoniou AC,Pharoah PD,McMullan G,Day NE,Ponder BA,Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001; 21: 118.
  • 8
    Bell DW,Varley JM,Szydlo TE,Kang DH,Wahrer DC,Shannon KE,Lubratovich M,Verselis SJ,Isselbacher KJ,Fraumeni JF,Birch JM,Li FP, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 252831.
  • 9
    Meijers-Heijboer H,Wijnen J,Vasen H,Wasielewski M,Wagner A,Hollestelle A,Elstrodt F,van den Bos R,de Snoo A,Fat GT,Brekelmans C,Jagmohan S, et al. CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 559.
  • 10
    CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004; 74: 117582.
  • 11
    Allinen M,Huusko P,Mantyniemi S,Launonen V,Winqvist R. Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 2001; 85: 20912.
  • 12
    Kilpivaara O,Vahteristo P,Falck J,Syrjakoski K,Eerola H,Easton D,Bartkova J,Lukas J,Heikkila P,Aittomaki K,Holli K,Blomqvist C, et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004; 111: 5437.
  • 13
    Seppala EH,Ikonen T,Mononen N,Autio V,Rokman A,Matikainen MP,Tammela TL,Schleutker J. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003; 89: 196670.
  • 14
    Weischer M,Bojesen SE,Tybjaerg-Hansen A,Axelsson CK,Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 2007; 25: 5763.
  • 15
    de Bock GH,Schutte M,Krol-Warmerdam EM,Seynaeve C,Blom J,Brekelmans CT,Meijers-Heijboer H,van Asperen CJ,Cornelisse CJ,Devilee P,Tollenaar RA,Klijn JG. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 2004; 41: 7315.
  • 16
    Schmidt MK,Tollenaar RA,de Kemp SR,Broeks A,Cornelisse CJ,Smit VT,Peterse JL,van Leeuwen FE,Van't Veer LJ. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 2007; 25; 649.
  • 17
    Dong X,Wang L,Taniguchi K,Wang X,Cunningham JM,McDonnell SK,Qian C,Marks AF,Slager SL,Peterson BJ,Smith DI,Cheville JC, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003; 72: 27080.
  • 18
    Dufault MR,Betz B,Wappenschmidt B,Hofmann W,Bandick K,Golla A,Pietschmann A,Nestle-Kramling C,Rhiem K,Huttner C,von Lindern C,Dall P, et al. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 2004; 110: 3205.
  • 19
    Cybulski C,Huzarski T,Gorski B,Masojc B,Mierzejewski M,Debniak T,Gliniewicz B,Matyjasik J,Zlowocka E,Kurzawski G,Sikorski A,Posmyk M, et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004; 64: 26779.
  • 20
    Lee SB,Kim SH,Bell DW,Wahrer DC,Schiripo TA,Jorczak MM,Sgroi DC,Garber JE,Li FP,Nichols KE,Varley JM,Godwin AK, et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res 2001; 61: 80627.
  • 21
    Wu X,Webster SR,Chen J. Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001; 276: 29714.
  • 22
    Falck J,Mailand N,Syljuasen RG,Bartek J,Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001; 410: 8427.
  • 23
    Falck J,Lukas C,Protopopova M,Lukas J,Selivanova G,Bartek J. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 2001; 20: 550310.
  • 24
    Li J,Williams BL,Haire LF,Goldberg M,Wilker E,Durocher D,Yaffe MB,Jackson SP,Smerdon SJ. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 2002; 9: 104554.
  • 25
    Walworth N,Davey S,Beach D. Fission yeast chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature 1993; 363: 36871.
  • 26
    Allen JB,Zhou Z,Siede W,Friedberg EC,Elledge SJ. The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. Genes Dev 1994; 8: 240115.
  • 27
    Weinert TA,Kiser GL,Hartwell LH. Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair. Genes Dev 1994; 8: 65265.
  • 28
    Murakami H,Okayama H. A kinase from fission yeast responsible for blocking mitosis in S phase. Nature 1995; 374: 81719.
  • 29
    Walworth NC,Bernards R. Rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint. Science 1996; 271: 3536.
  • 30
    Matsuoka S,Huang M,Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998; 282: 18937.
  • 31
    Chehab NH,Malikzay A,Appel M,Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000; 14: 27888.
  • 32
    Hirao A,Kong YY,Matsuoka S,Wakeham A,Ruland J,Yoshida H,Liu D,Elledge SJ,Mak TW. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000; 287: 18247.
  • 33
    Shieh SY,Ahn J,Tamai K,Taya Y,Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14: 289300.
  • 34
    Lee JS,Collins KM,Brown AL,Lee CH,Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000; 404: 2014.
  • 35
    Jack MT,Woo RA,Hirao A,Cheung A,Mak TW,Lee PW. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA 2002; 99: 98259.
  • 36
    Takai H,Naka K,Okada Y. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002; 21: 5195205.
  • 37
    Hirao A,Cheung A,Duncan G,Girard PM,Elia AJ,Wakeham A,Okada H,Sarkissian T,Wong JA,Sakai T,De Stanchina E,Bristow RG, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 2002; 22: 652132.
  • 38
    Bahassi el M,Penner CG,Robbins SB,Tichy E,Feliciano E,Yin M,Liang L,Deng L,Tischfield JA,Stambrook PJ. The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model. Mutat Res 2007; 616: 2019.
  • 39
    McPherson JP,Lemmers B,Hirao A. Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev 2004; 18: 114453.
  • 40
    Kim SS,Cao L,Li C,Xu X,Huber LJ,Chodosh LA,Deng CX. Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1. Mol Cell Biol 2004; 4: 9498507.
  • 41
    Einarsdottir K,Humphreys K,Bonnard C,Palmgren J,Iles MM,Sjolander A,Li Y,Chia KS,Liu ET,Hall P,Liu J,Wedren S. Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk. PLoS Med 2006; 3: e168.
  • 42
    Kolonel LN,Henderson BE,Hankin JH,Nomura AM,Wilkens LR,Pike MC,Stram DO,Monroe KR,Earle ME,Nagamine FS. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000; 151: 34657.
  • 43
    Miller CW,Ikezoe T,Krug U,Hofmann WK,Tavor S,Vegesna V,Tsukasaki K,Takeuchi S,Koeffler HP. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 2002; 33: 1721.
  • 44
    Sodha N,Bullock S,Taylor R,Mitchell G,Guertl-Lackner B,Williams RD,Bevan S,Bishop K,McGuire S,Houlston RS,Eeles RA. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer 2002; 87: 14458.
  • 45
    Hangaishi A,Ogawa S,Qiao Y,Wang L,Hosoya N,Yuji K,Imai Y,Takeuchi K,Miyawaki S,Hirai H. Mutations of Chk2 in primary hematopoietic neoplasms. Blood 2002; 99: 30757.
  • 46
    Durocher D,Jackson SP. The FHA domain. FEBS Lett 2002; 513: 5866.
  • 47
    Sun Z,Hsiao J,Fay DS,Stern DF. Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint. Science 1998; 281: 2724.
  • 48
    Combet C,Blanchet C,Geourjon C,Deleage G. NPS@: network protein sequence analysis. Trends Biochem Sci 2000; 25: 147510.
  • 49
    Offit K,Pierce H,Kirchhoff T. Frequency of CHEK2*1100delC in NewYork breast cancer cases and controls. BMC Med Genet 2003; 4: 1.
  • 50
    Shaag A,Walsh T,Renbaum P,Kirchhoff T,Nafa K,Shiovitz S,Mandell JB,Welcsh P,Lee MK,Ellis N,Offit K,Levy-Lahad E, et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 2005; 14: 55563.
  • 51
    Huang J,Domchek SM,Brose MS,Rebbeck TR,Nathanson KL,Weber BL. Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers. J Med Genet 2004; 41: e120.
  • 52
    Mateus Pereira LH,Sigurdson AJ,Doody MM,Pineda MA,Alexander BH,Greene MH,Struewing JP. CHEK2:1100delC and female breast cancer in the United States. Int J Cancer 2004; 112: 5413.